RxDoctor Payments DataLook up a doctor →

Parshaw Dorriz, MD

Neurology · Mission Viejo, CANPI 1972940625

Payments from drug & device makers

$1,529,483in general payments, 2019–2025

Across 580 payments — averaging $2637.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ceribell, Inc.$1.5M
  • AbbVie$3K
  • UCB, Inc.$953
  • Acadia Pharmaceuticals Inc$738
  • SK Life Science, Inc.$725
  • Biogen$592
  • plus $4K from 49 others

What the payments were for

  • Consulting fees$1,512,76799%
  • Speaking & faculty fees$450%
  • Travel & lodging$4,0910%
  • Food & beverage$12,4481%
  • Education$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,529,483 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$191,809
Medicare patients
475
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LamictalLamotrigine13$49,949
BriviactBrivaracetam19$31,131
KeppraLevetiracetam13$22,802
Oxtellar XrOxcarbazepine16$16,256
Levetiracetam157$5,966
Lacosamide35$4,827
Divalproex Sodium42$2,208
Lamotrigine103$2,174
Oxcarbazepine25$1,331
Memantine Hcl44$1,296
Gabapentin39$1,032
Donepezil Hcl107$939
Duloxetine Hcl11$769
Phenobarbital37$718
Carbidopa-LevodopaCarbidopa/Levodopa25$640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$953$31,13119 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$521$16,25616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →